Updates in the Management of Clostridium Difficile for Adults

Kimberly E. Ng, PharmD, BCPS

Disclosures

US Pharmacist. 2019;44(4):HS9-HS12. 

In This Article

Rifaximin

Rifaximin inhibits bacterial RNA synthesis by binding to bacterial DNA-dependent RNA polymerase. Rifaximin is recommended in the guidelines as an adjunctive post-vancomycin treatment regimen for patients with recurrent CDI. It is not absorbed and therefore has minimal systemic effects, but there are concerns regarding potential resistance with rifaximin use. Reported common side effects include dizziness, fatigue, and nausea.[4,6,10]

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....